We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
We will guide you from your first visit to the centre, allowing you to find all the departments and make the most of our facilities. Whatever the reason for your visit, we will explain how to get about the hospital.
Dr. Lucas Moreno
SIOPEN promotes research and the implementation of clinical trials to improve clinical practice in this type of childhood tumor.
Dr. Lucas Moreno, head of the Pediatric Oncology and Hematology Service at Vall d'Hebron University Hospital and of the Childhood Cancer and Blood Disorders group at Vall d'Hebron Research Institute (VHIR), has been appointed as president-elect of the European Neuroblastoma Group (SIOPEN Association, part of the International Society of Pediatric Oncology in Europe) in 2023. This is a group formed by centers from 25 European countries along with Singapore, Australia and Israel to promote the implementation of clinical trials for the treatment of neuroblastoma and other research projects to improve clinical practice for this aggressive childhood tumor.
Dr. Moreno will serve as president-elect during 2023, to become president of the group from 2024 for two to four years. His election marks the first time a Spaniard has led SIOPEN. "It is an opportunity to lead the development of new treatments and research projects that, carried out collaboratively among the different centers in the group, can have an impact worldwide", says Dr. Moreno.
Among the studies promoted by SIOPEN is BEACON, a clinical trial for the treatment of relapsed neuroblastoma. Promising results have recently been obtained using innovative therapy combinations for these patients, and the BEACON2 study will be launched soon.
Paediatric Oncology and Haematology,
Children's Hospital and Woman's Hospital
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to email@example.com, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut.
Purpose: Manage the user’s contact information.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.